Literature DB >> 16373660

Tumor vascular targeting therapy with viral vectors.

Yanzheng Liu1, Albert Deisseroth.   

Abstract

Tumor angiogenesis is crucial for the progression and metastasis of cancer. The vasculature of tumor tissue is different from normal vasculature. Therefore, tumor vascular targeting therapy could represent an effective therapeutic strategy with which to suppress both primary tumor growth and tumor metastasis. The use of viral vectors for tumor vascular targeting therapy is a promising strategy based on the unique properties of viral vectors. In order to circumvent the potential problems of antiviral neutralizing antibodies, poor access to extravascular tumor tissue, and toxicities to normal tissue, viral vectors need to be modified to target the tumor endothelial cells. Viral vectors that could be used for tumor vascular targeting therapy include adenoviral vectors, adeno-associated viral vectors, retroviral vectors, lentiviral vectors, measles virus, and herpes simplex viral vectors. In this review, we will summarize the strategies available for targeting viral vectors for tumor vascular targeting therapy.

Entities:  

Mesh:

Year:  2005        PMID: 16373660     DOI: 10.1182/blood-2005-10-4114

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  21 in total

1.  Use of adenoviral vectors to target chemotherapy to tumor vascular endothelial cells suppresses growth of breast cancer and melanoma.

Authors:  Pingchuan Li; Yanzheng Liu; Jonathan Maynard; Yucheng Tang; Albert Deisseroth
Journal:  Mol Ther       Date:  2010-02-23       Impact factor: 11.454

2.  Changing viral tropism using immunoliposomes alters the stability of gene expression: implications for viral vector design.

Authors:  Peng H Tan; Shao-An Xue; Bin Wei; Angelika Holler; Ralf-Holger Voss; Andrew J T George
Journal:  Mol Med       Date:  2007 Mar-Apr       Impact factor: 6.354

3.  Tumor vascular targeted delivery of polymer-conjugated adenovirus vector for cancer gene therapy.

Authors:  Xinglei Yao; Yasuo Yoshioka; Tomohiro Morishige; Yusuke Eto; Shogo Narimatsu; Yasuaki Kawai; Hiroyuki Mizuguchi; Jian-Qing Gao; Yohei Mukai; Naoki Okada; Shinsaku Nakagawa
Journal:  Mol Ther       Date:  2011-06-14       Impact factor: 11.454

4.  Annexin-directed β-glucuronidase for the targeted treatment of solid tumors.

Authors:  Katrin P Guillen; Eliza A Ruben; Needa Virani; Roger G Harrison
Journal:  Protein Eng Des Sel       Date:  2016-12-15       Impact factor: 1.650

Review 5.  Targeting anticancer drugs to tumor vasculature using cationic liposomes.

Authors:  Amr S Abu Lila; Tatsuhiro Ishida; Hiroshi Kiwada
Journal:  Pharm Res       Date:  2010-03-24       Impact factor: 4.200

6.  Intravascularly administered RGD-displaying measles viruses bind to and infect neovessel endothelial cells in vivo.

Authors:  Hooi Tin Ong; Theodore R Trejo; Linh D Pham; Ann L Oberg; Stephen J Russell; Kah-Whye Peng
Journal:  Mol Ther       Date:  2009-03-10       Impact factor: 11.454

7.  A novel Flk1-TVA transgenic mouse model for gene delivery to angiogenic vasculature.

Authors:  Virginie S Vervoort; Mark Lu; Fatima Valencia; Jacqueline Lesperance; Georg Breier; Robert Oshima; Elena B Pasquale
Journal:  Transgenic Res       Date:  2007-11-20       Impact factor: 2.788

8.  Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor.

Authors:  Yuqi Jing; Caili Tong; Jin Zhang; Takafumi Nakamura; Ianko Iankov; Stephen J Russell; Jaime R Merchan
Journal:  Cancer Res       Date:  2009-02-10       Impact factor: 12.701

9.  Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus.

Authors:  Timothy Kottke; Feorillo Galivo; Phonphimon Wongthida; Rosa Maria Diaz; Jill Thompson; Dragan Jevremovic; Glen N Barber; Geoff Hall; John Chester; Peter Selby; Kevin Harrington; Alan Melcher; Richard G Vile
Journal:  Mol Ther       Date:  2008-04-22       Impact factor: 11.454

10.  Endoglin is necessary for angiogenesis in human ovarian carcinoma-derived primary endothelial cells.

Authors:  Yan Xu; Dan Wang; Li-Mei Zhao; Xi-Long Zhao; Jun-Jie Shen; Yao Xie; Li-Li Cao; Zhen-Bo Chen; Yan-Mei Luo; Bi-Hui Bao; Zhi-Qing Liang
Journal:  Cancer Biol Ther       Date:  2013-08-05       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.